MilliporeSigma has partnered with Angiex, a Cambridge, Massachusetts-headquartered biotechnology company, in the development of Angiex’ lead oncology antibody drug conjugate candidate.

The collaboration with Angiex is the first project to be undertaken at MilliporeSigma’s new biodevelopment center in Massachusetts. MilliporeSigma will give Angiex access to end-to-end process development tools, education programs, and training.

MilliporeSigma’s BioReliance End-to-End Solutions, part of its process solutions business area, includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification, and set-up for commercialization.

MilliporeSigma will inaugurate its new biodevelopment center in Burlington, Massachusetts, in October 2017.

Source: MilliporeSigma and Angiex